Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E: 463 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
463
Total FAERS Reports
5 (1.1%)
Deaths Reported
122
Hospitalizations
463
As Primary/Secondary Suspect
20
Life-Threatening
10
Disabilities

First Report: 201403 · Latest Report: 20250801

What Are the Most Common RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Side Effects?

#1 Most Reported
Herpes zoster
112 reports (24.2%)
#2 Most Reported
Pain
93 reports (20.1%)
#3 Most Reported
Vaccination failure
74 reports (16.0%)

All RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Herpes zoster 112 24.2% 0 11
Pain 93 20.1% 1 24
Vaccination failure 74 16.0% 0 8
Rash 64 13.8% 0 15
Pyrexia 50 10.8% 2 20
Fatigue 48 10.4% 0 11
Drug ineffective 44 9.5% 0 14
Nausea 40 8.6% 0 10
Pain in extremity 38 8.2% 0 15
Arthralgia 36 7.8% 0 9
Dyspnoea 33 7.1% 2 14
Headache 33 7.1% 0 8
Pruritus 32 6.9% 0 5
Diarrhoea 31 6.7% 1 11
Asthenia 27 5.8% 1 16
Paraesthesia 25 5.4% 0 4
Erythema 24 5.2% 0 7
Malaise 24 5.2% 0 9
Dizziness 23 5.0% 0 8
Injection site pain 23 5.0% 0 2

Who Reports RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Side Effects? Age & Gender Data

Gender: 66.8% female, 33.2% male. Average age: 64.0 years. Most reports from: US. View detailed demographics →

Is RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Getting Safer? Reports by Year

YearReportsDeathsHosp.
2014 1 0 0
2016 1 0 0
2017 2 0 1
2018 26 0 6
2019 34 0 9
2020 48 0 13
2021 56 0 13
2022 32 1 3
2023 50 1 15
2024 30 1 15
2025 14 0 9

View full timeline →

What Is RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E Used For?

IndicationReports
Prophylaxis 233
Product used for unknown indication 75
Immunisation 52
Herpes zoster immunisation 22
Herpes zoster 17
Antiviral prophylaxis 5

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs Alternatives: Which Is Safer?

RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REGADENOSON RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REGORAFENIB RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REGORAFENIB\REGORAFENIB RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs RELATLIMAB RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs RELPAX RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs RELUGOLIX RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REMDESIVIR RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REMERON RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REMICADE RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E vs REMIFENTANIL

Official FDA Label for RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E

Official prescribing information from the FDA-approved drug label.